RANBP3L Antibody
Description
Pan-Cancer Analysis
RANBP3L expression is significantly downregulated in 18 cancer types, including liver hepatocellular carcinoma (LIHC), compared to normal tissues . Reduced RANBP3L correlates with:
Renal Cell Carcinoma (KIRC)
-
Loss of RANBP3L induces tumor-like phenotypes in renal epithelial cells, mimicking KIRC morphology and gene expression .
-
Prognostic gene signatures linked to RANBP3L loss are translatable to human KIRC samples .
Immune Modulation and Tumor Microenvironment
In LIHC, RANBP3L expression correlates with immune cell infiltration:
| Immune Cell Type | Correlation with RANBP3L | Impact on Prognosis |
|---|---|---|
| B cells, CD8+ T cells | Positive | Improved OS |
| Macrophages | Negative | Reduced tumor-free survival |
| Neutrophils | Variable | Linked to shorter DSS |
Therapeutic Implications
-
LIHC: High RANBP3L expression predicts better survival, suggesting utility as a prognostic biomarker .
-
KIRC: RANBP3L loss promotes oncogenic transformation, highlighting its role as a tumor suppressor .
-
CML Context: While studies focus on the related protein RanBP3, its role in chemosensitivity (e.g., imatinib response) underscores potential parallels for RANBP3L in therapeutic targeting .
Future Research Directions
Product Specs
Target Background
- A single nucleotide polymorphism (SNP), rs16902947 in RANBP3L located at 5p13.2, has been significantly associated with Benign Prostate Hyperplasia (p = .01). Additionally, this SNP has been linked to alpha-adrenergic receptor antagonist drug effect in Benign Prostate Hyperplasia (p = .0388). PMID: 28787260
- Research has demonstrated that RANBP3L, functioning as a nuclear exporter for BMP-specific Smads, plays a critical role in terminating BMP signaling and regulating mesenchymal stem cell differentiation. PMID: 25755279
